McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma cell leukemia and myeloma. lancet 1983; 2:822-824.
Lazarus HM, Phillips GL, Herzig RH, Hard DD, Wolff SN, Herzig GP. Development of high-dose melphalan and hematopoietic stem cell transplantation: 25 years later. J Clin Oncor 2008; 26:2240-2243.
Smith A, Wislov F, Samson D. Guidelines for the diagnosis and management of multiple myeloma 2005. Br J Hematol 2006; 132:410-451.
Blade J, Esteve J, Ribes S, Martinez C, Rovira M, Urbano-Ispizua A other. High-dose therapy autologous/intensive therapy and continuation of standard chemotherapy in multiple myeloma in first remission. Results from a single-center, non-randomized study. Bone marrow transplantation the year of 2000; 26:845-849.
Attal M, Halso JL, Facon T, Gilhot F, Doyen C, Fujibet JG. other. Single versus double autologous stem cell transplantation for multiple myeloma. N English J Medicine 2003; 349:2495-2502.
Child JA, Morgan GJ, Davis FE, Owen RG, Bell SE, Hawkins K. other. High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N English J Medicine 2003; 348: 1875-1883.
Attal M, Halsaw JL, Stoppa AM, Sotto JJ, Fujibet JG, Rossi JF. other. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroup Français du Mierome. N English J Medicine 1996; 335:91-97.
Also JL. Stem cell transplantation in multiple myeloma (0, 1, or 2). Kuru Opin Onkor Year 2005; 17:93-98.
Lenhoff S, Joos M, Holmberg E, Turesson I, Westin J, Nielsen JL. other. Impact of high-dose therapy with autologous stem cell support on survival in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Research Group. blood the year of 2000; 95:7~11.
Blade J, San Miguel JF, Fontanillas M, Esteve J, Maldonado J, Alcalá A. other. Increasing conventional chemotherapy does not improve survival in multiple myeloma: long-term results from two PETHEMA trials including 914 patients. Hematol J 2001. 2:272-278.
Ferman JP, Bresignac S. The role of autologous stem cell transplantation in the management of multiple myeloma. Pasol Viol (Paris) 1999; 47:199-202.
Russell NH, Sidlo R, McCann S, Potter MN, Craddock C, Towlson K. other. Use of national transplant registries to benchmark transplant outcomes for patients undergoing autologous and allogeneic stem cell transplants in the UK and Ireland. Br J Hematol 2004; 124:499-503.
Blade J, Samson D, Rees D, Upperley J, Bjorkstrand B, Garton G. other. Criteria for assessing disease response and progression in multiple myeloma patients treated with high-dose therapy and hematopoietic stem cell transplantation. EBMT Myeloma Subcommittee. European Blood and Marrow Transplant Group. Br J Hematol 1998; 102:1115-1123.
Kastritis E, Zervas K, Simeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N. other. Improving the survival of patients with multiple myeloma after the introduction of new drugs and the applicability of the International Staging System (ISS): An analysis of the Greek Myeloma Study Group (GMSG). leukemia 2009; twenty three:1152-1157.
Kumar SK, Rajkumar SV, Dispenzieri A, Lacey MQ, Heyman SR, Bouadi FK. other. Improved survival and efficacy of new treatments in multiple myeloma. blood 2008; 111:2516-2520.
Blade J, Kyle RA, Greip PR. We present the characteristics and prognosis of 72 patients with multiple myeloma aged <40 years. Br J Hematol 1996; 93:345-351.
Brenner H, Gondos A, Prut D. Recently, long-term survival rates for young patients with multiple myeloma have significantly improved. blood 2008; 111:2521-2526.
Cheema PK, Zadeh S, Kukreti V, Rees D, Chen C, Trudel S. other. If the patient is under 40 years of age, the prognosis for multiple myeloma patients undergoing upfront autologous stem cell transplantation is poor. bio blood bone marrow transplant 2009; 15:686-693.
Bensinger WI. The role of autologous and allogeneic stem cell transplantation in myeloma. leukemia 2009; twenty three:442-448.
Rowe VJ, Rowe H, Webb MJ. Autologous stem cell transplantation for multiple myeloma. N English J Medicine 2009; 361: 1118-1119; Author reply 1119.
Dingli D, Pacheco JM, Nowakowski GS, Kumar SK, Dispenzieri A, Heyman SR. other. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncor 2007; twenty five:4933-4937.
Gee B, Cole B, Lee T, Brauman G, James K, Johnston D. other. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncor 1998; 16:2834-2839.
Also JL. Induction therapy in multiple myeloma. Hematology Am Soc Hematol Educ Program 2008, 306-312.
Harousseau JL, Attal M, Leroux X, Troncy J, Pegoly B, Stoppa AM. other. Bortezomib and dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results from the IFM phase II trial. haematologica 2006; 91:1498-1505.
Rokhorst HM, Schmidwolff I, Sonnefeld P, van der Holt B, Martin H, Burge R. otherThalidomide in induction therapy increases very good partial response rates both before and after high-dose therapy in previously untreated multiple myeloma. haematologica 2008; 93:124-127.
Rossinol L, Oriol A, Mateos MV, Threda A, Garcia Sanchez P, Gutierrez N. other. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as an induction regimen before autologous stem cell transplantation in young patients with multiple myeloma: Efficacy and clinical implications of tumor response kinetics. J Clin Oncor 2007; twenty five:4452-4458.
Dury BG, Halsaw JL, Miguel JS, Blade J, Barlogie B, Anderson K. other. International harmonized response criteria for multiple myeloma. leukemia 2006; 20: 1467 – 1473.
Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant endpoints and new drug approvals for myeloma. leukemia 2008; twenty two:231-239.
